Ken Griffin Ardelyx, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ardelyx, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 193,600 shares of ARDX stock, worth $1.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

193,600

Previous 258,400 25.08%

Holding current value

$1.12 Million

Previous $1.89 Million 23.97%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.89 - $9.31 $1.12 Million - $1.77 Million	-190,073 Reduced 42.17%	260,632 $1.93 Million
Q1 2024 May 15, 2024	BUY	$6.05 - $9.74 $1.72 Million - $2.77 Million	284,402 Added 171.01%	450,705 $3.29 Million
Q4 2023 Feb 14, 2024	SELL	$3.29 - $6.64 $160,838 - $324,609	-48,887 Reduced 22.72%	166,303 $1.03 Million
Q3 2023 Nov 14, 2023	BUY	$3.3 - $4.83 $485,835 - $711,087	147,223 Added 216.61%	215,190 $877,000
Q2 2023 Aug 14, 2023	SELL	$3.23 - $4.95 $589,536 - $903,469	-182,519 Reduced 72.87%	67,967 $230,000
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $646,684 - $1.16 Million	241,300 Added 2626.82%	250,486 $1.2 Million
Q4 2022 Feb 14, 2023	SELL	$1.22 - $2.85 $141,940 - $331,583	-116,345 Reduced 92.68%	9,186 $26,000
Q3 2022 Nov 14, 2022	SELL	$0.59 - $1.44 $183,510 - $447,890	-311,035 Reduced 71.25%	125,531 $150,000
Q2 2022 Aug 15, 2022	BUY	$0.51 - $1.17 $131,183 - $300,950	257,223 Added 143.43%	436,566 $258,000
Q4 2021 Feb 14, 2022	SELL	$0.86 - $1.7 $29,248 - $57,817	-34,010 Reduced 15.94%	179,343 $197,000
Q3 2021 Nov 15, 2021	BUY	$1.27 - $8.17 $113,766 - $731,868	89,580 Added 72.37%	213,353 $282,000
Q2 2021 Aug 16, 2021	BUY	$6.55 - $8.98 $452,794 - $620,778	69,129 Added 126.51%	123,773 $938,000
Q1 2021 May 17, 2021	SELL	$6.1 - $7.69 $121,890 - $153,661	-19,982 Reduced 26.78%	54,644 $362,000
Q4 2020 Feb 16, 2021	BUY	$5.05 - $7.1 $124,149 - $174,546	24,584 Added 49.13%	74,626 $483,000
Q3 2020 Nov 16, 2020	SELL	$5.25 - $7.08 $780,318 - $1.05 Million	-148,632 Reduced 74.81%	50,042 $262,000
Q1 2020 May 15, 2020	BUY	$4.35 - $8.79 $268,033 - $541,613	61,617 Added 44.96%	198,674 $1.13 Million
Q4 2019 Feb 14, 2020	BUY	$4.23 - $8.29 $495,827 - $971,728	117,217 Added 590.81%	137,057 $1.03 Million
Q3 2019 Nov 14, 2019	BUY	$2.15 - $6.28 $12,829 - $37,472	5,967 Added 43.01%	19,840 $93,000
Q2 2019 Aug 14, 2019	SELL	$2.49 - $3.73 $112,889 - $169,107	-45,337 Reduced 76.57%	13,873 $37,000
Q4 2018 Feb 14, 2019	BUY	$1.66 - $4.16 $17,977 - $45,052	10,830 Added 22.39%	59,210 $105,000
Q3 2018 Nov 13, 2018	BUY	$3.75 - $4.65 $58,638 - $72,712	15,637 Added 47.76%	48,380 $0
Q2 2018 Aug 10, 2018	BUY	$3.7 - $5.8 $18,781 - $29,440	5,076 Added 18.35%	32,743 $0
Q1 2018 May 11, 2018	SELL	$5.05 - $7.9 $17,346 - $27,136	-3,435 Reduced 11.04%	27,667 $140,000
Q4 2017 Feb 09, 2018	SELL	$4.85 - $7.8 $133,006 - $213,907	-27,424 Reduced 46.86%	31,102 $205,000
Q3 2017 Nov 09, 2017	BUY	$4.35 - $5.7 $254,588 - $333,598	58,526	58,526 $328,000

Others Institutions Holding ARDX

# of Institutions

209

Shares Held

144M

Call Options Held

1.01M

Put Options Held

1.43M

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $892M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account